Telbivudine therapy may shape CD4+ T-cell response to prevent liver fibrosis in patients with chronic hepatitis B

2014 ◽  
Vol 35 (3) ◽  
pp. 834-845 ◽  
Author(s):  
Jing Li ◽  
Minglei Jia ◽  
Yun Liu ◽  
Weimin She ◽  
Lei Li ◽  
...  
2012 ◽  
Vol 42 (5) ◽  
pp. 1180-1191 ◽  
Author(s):  
Wei Wu ◽  
Yu Shi ◽  
Shuping Li ◽  
Yun Zhang ◽  
Yanning Liu ◽  
...  

2011 ◽  
Vol 54 ◽  
pp. S114 ◽  
Author(s):  
A. de Niet ◽  
M.J. Tempelmans Plat-Sinnige ◽  
R.B. Takkenberg ◽  
H.W. Reesink ◽  
R.A.W. van Lier ◽  
...  

2004 ◽  
Vol 24 (4) ◽  
pp. 308-315 ◽  
Author(s):  
Oscar Pontesilli ◽  
Andeltje B. van Nunen ◽  
Debby van Riel ◽  
Patrizia Carotenuto ◽  
Hubert G. Niesters ◽  
...  

2013 ◽  
Vol 94 (12) ◽  
pp. 2717-2723 ◽  
Author(s):  
Xiaoling Chen ◽  
Wenbo Wang ◽  
Shufeng Wang ◽  
Gang Meng ◽  
Mengjun Zhang ◽  
...  

Hepatitis B virus (HBV) infection is a worldwide public health problem. HBV-specific CD8+ CTLs are vital for viral clearance. Identification of immunodominant CTL epitopes from HBV-associated antigens is necessary for therapeutic vaccine development. We showed that the HLA-A*1101 allele is one of the most common alleles in both healthy individuals and chronic hepatitis B (CHB) patients in the Chongqing area, China. However, less than 10 % of epitopes of HBV-associated antigens have been identified in an HLA-A*1101 context. Here, we describe an immunodominant CD8+ T-cell response targeting a hepatitis B surface antigen determinant (HBs295–304) restricted by HLA-A*1101 in both healthy individuals and CHB patients. Moreover, HBs295–304 is more immunogenic for CTL induction than a known naturally HLA-A*1101-processed epitope from hepatitis B core antigen (HBc88–96). Therefore, the newly identified epitope, HBs295–304, will benefit the development of immunotherapeutic approaches for HBV infection.


2009 ◽  
Vol 83 (19) ◽  
pp. 9652-9662 ◽  
Author(s):  
Shinichi Asabe ◽  
Stefan F. Wieland ◽  
Pratip K. Chattopadhyay ◽  
Mario Roederer ◽  
Ronald E. Engle ◽  
...  

ABSTRACT The impact of virus dose on the outcome of infection is poorly understood. In this study we show that, for hepatitis B virus (HBV), the size of the inoculum contributes to the kinetics of viral spread and immunological priming, which then determine the outcome of infection. Adult chimpanzees were infected with a serially diluted monoclonal HBV inoculum. Unexpectedly, despite vastly different viral kinetics, both high-dose inocula (1010 genome equivalents [GE] per animal) and low-dose inocula (10° GE per animal) primed the CD4 T-cell response after logarithmic spread was detectable, allowing infection of 100% of hepatocytes and requiring prolonged immunopathology before clearance occurred. In contrast, intermediate (107 and 104 GE) inocula primed the T-cell response before detectable logarithmic spread and were abruptly terminated with minimal immunopathology before 0.1% of hepatocytes were infected. Surprisingly, a dosage of 101 GE primed the T-cell response after all hepatocytes were infected and caused either prolonged or persistent infection with severe immunopathology. Finally, CD4 T-cell depletion before inoculation of a normally rapidly controlled inoculum precluded T-cell priming and caused persistent infection with minimal immunopathology. These results suggest that the relationship between the kinetics of viral spread and CD4 T-cell priming determines the outcome of HBV infection.


2009 ◽  
Vol 15 (3) ◽  
pp. 292-299 ◽  
Author(s):  
Ying Luo ◽  
Chung Mau Lo ◽  
Cindy K. Cheung ◽  
George K. Lau ◽  
John Wong

Sign in / Sign up

Export Citation Format

Share Document